Press release
KalVista Pharmaceuticals Presents Data Demonstrating KVD900 Achieves Rapid Exposure and Improves Outcomes as Oral On-Demand Treatment of HAE
– KVD900 Phase 2 data presented at American College of Allergy, Asthma & Immunology Annual Scientific Meeting – CAMBRIDGE, Mass. & SALISBURY,
About this update from Kalvista Pharmaceuticals, Inc.
[{"type":"text","content":"\n– KVD900 Phase 2 data presented at American College of Allergy, Asthma & Immunology Annual Scientific Meeting –\n\n CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--\nKalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced data presented at American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting. Data presentations included an oral presentation and poster presentation on Phase 2 data for KVD900, KalVista’s lead program for oral on-demand treatment of hereditary angioedema (HAE) attacks.\n\n“Current guidelines recommend effective on-demand therapy for every patient with HAE to reduce symptom severity and attack duration,” said Jonathan Bernstein, FAAAAI, FACAAI, FACP, M.D., University of Cincinnati College of Medicine and Bernstein Clinical Research Center, LLC. “Treatment of HAE attacks with KVD900 achieved rapid plasma exposure which was associated with faster improvements in initial symptom relief compared with placebo. As the first oral on-demand treatment to demonstrate this early therapeutic effect for patients, KVD900 may represent a remarkable advancement for management of the disease.”\n\nOral Presentation: On-Demand Oral Treatment with KVD900 for HAE Attacks Achieves Rapid Exposures and Improves Patient Outcomes\n\n\nKVD900 was rapidly absorbed, with measurable concentrations detected within 15 minutes\n\n\nPlasma levels reached peak concentration within 1 hour of administration\n\n\nMedian time to symptom improvement was significantly shorter with KVD900 than with placebo (1.6 vs 9.0 hours, p","length":2135,"tagName":"div"}]